Tissue and organ damage and loss are normally treated using allogeneic transplants, the patientís own tissue, medical devices and pharmaceutical drugs, however all these treatments have their own inherent shortcomings. To overcome the disadvantages of using traditional methods, the concept of regenerative medicine evolved with the advancement in technology. Cartilage regeneration is a kind of regenerative medicine used to restore damaged articular/joint cartilage. The global cartilage regeneration product market is estimated to be around $300 million in 2014.
Cartilage regeneration market is segmented by procedure, and emerging technologies. Based on procedure, the cartilage market is further segmented into cell-based approaches such as autologous chondrocytes transplantation, stem cell, growth factor technology, and cell-based cartilage resurfacing, cell-free composites and scaffolds, microfracturing, subchondroplasty, osteochondral allograft, osteochondral autograft transplantation, and meniscus transplant.
Of all, autologous chondrocytes transplantation, microfractures, and bio-scaffolds are expected to grow at high rates due to higher efficiency over other cell base therapies. Further, there are about 5.4 million potential patients who will require joint and cartilage regeneration procedures by 2019 in U.S. alone, a significant factor driving the overall market of cartilage regeneration market. The growing aging population triggering the incidences of articular damage in knee will also propel the market of cartilage regeneration. On the other hand, the cost of cartilage regeneration techniques will restrain the market in coming years.
Emerging technologies that transforms the cartilage regeneration market are cartilage restoration technologies, gene therapy, stem cells, and tissue engineering. Cartilage restoration technology is broadly divided into two types such as two-stage and one-stage techniques and few of these techniques are still under clinical trial in U.S. However, these techniques are well adopted among physicians in Europe.
Geographic analysis reveals that Europe is the largest contributor to the global cartilage regeneration market. However, Asia will be the fastest growing region for cartilage regeneration market. The North America, on the other hand, is poised to grow at moderate growth rate due to the stringent regulatory status set by FDA.
The key players in the market are Anika Therapeutics (U.S.), Biomet (U.S.), BioTissue Technologies (Germany), DePuy (Johnson & Johnson) (U.S.), Genzyme (U.S.), CellGenix (Germany), Advanced Technologies and Regenerative Medicine (U.S.) , EMD Serono (U.S.), Sanofi Aventis (France), Smith & Nephew (U.K.), and Zimmer (U.S.).